What is Leerink Partnrs’ Forecast for HALO FY2025 Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research note issued on Sunday, January 12th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $4.96 for the year, down from their previous forecast of $5.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.57 EPS, FY2026 earnings at $7.05 EPS, FY2027 earnings at $8.77 EPS and FY2028 earnings at $9.16 EPS.

Several other analysts have also weighed in on the company. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $54.51 on Wednesday. The firm has a fifty day simple moving average of $49.83 and a two-hundred day simple moving average of $54.06. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $6.94 billion, a P/E ratio of 18.05, a PEG ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Congress Asset Management Co. boosted its stake in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after buying an additional 856,200 shares in the last quarter. Boston Trust Walden Corp boosted its position in Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Finally, South Street Advisors LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.